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To the Editor: Many patients in Africa present with HIV for 
the first time when they develop an opportunistic infection 
such as toxoplasmic encephalitis (TE). Optimal management of 
opportunistic infections such as TE is important in improving 
health and allowing patients to benefit from the expanding 
roll-out of highly active antiretroviral therapy (HAART).1-3 
Possible treatment regimens for TE include pyrimethamine 
plus sulfadiazine (P+S), pyrimethamine plus clindamycin 
(P+C), co-trimoxazole, and atovaquone. 
The aim of this review was to determine which therapy was 
most effective for treating HIV-infected patients presenting 
with a first episode of TE. Primary and secondary prophylaxis 
of TE were not considered. A full version of this review is 
available in the Cochrane library.4 
Methods
Treatment regimens were compared with regard to clinical and 
radiological response, mortality, morbidity and serious adverse 
events. 
Criteria for considering studies for this review were that 
studies be randomised controlled trials, and that participants 
be HIV-infected adults over 18 years of age with radiologically 
or histologically diagnosed TE. Both patients receiving and 
not receiving HAART were included. Types of interventions 
considered were those in which antibiotics were given alone or 
in combination for the treatment of TE. 
Primary outcomes were: (i) mortality defined as death 
during the follow-up period of the study (where possible, 
death due to TE was examined separately from death due 
to other causes); (ii) clinical response to treatment; (iii) 
neurological outcome; and (iv) serious adverse events (as 
defined by trial researchers). 
Secondary outcomes were: (i) radiological response to 
treatment; and (ii) minor adverse events (as defined by trial 
researchers). 
The HIV/AIDS Collaborative Review Group Search Strategy 
provides further details on the search strategy used to identify 
studies. 
Results
Searches revealed almost 1 000 studies related to TE treatment. 
The majority investigated prophylaxis or were not randomised. 
Only 3 studies were felt to be of sufficient quality to merit 
inclusion. A list of excluded studies and the reason for 
exclusion can be found in the full review.4
Dannemann et al.5 and Katlama et al.6 compared P+S 
with P+C. Torre et al.7 compared P+S with trimethoprim-
sulfamethoxazole (TMP-SMX). All 3 protocols allowed 
crossover to the other treatment arm at the discretion of 
the investigators if patients were not responding or were 
suffering from severe adverse events. For the purposes of this 
review clinical outcomes were analysed as complete or partial 
resolution versus failure. Patients who crossed over or who 
were lost to follow-up were analysed as failures. 
Dannemann et al.5 assessed 59 patients. Five of 26 patients 
(19%) randomised to P+C died in the first 6 weeks compared 
with 2 of the 33 patients (6%) randomised to P+S (relative 
risk (RR) 3.17; 95% confidence interval (CI) 0.67 - 15.06). 
Complete or partial resolution (defined as resolution of TE or 
a greater than 50% improvement in the graded neurological 
examination) was obtained in 12 patients (46.2%) receiving 
P+C v. 16 patients (48.5%) receiving P+S (RR 0.95, 95% CI 
0.55 - 1.64). Radiological outcomes were analysed as intention 
to treat regardless of whether patients crossed over or not. 
Nineteen patients (73%) randomised to P+C and 20 patients 
(61%) randomised to P+S had complete or partial radiological 
responses at 6 weeks (RR 1.21, 95% CI 0.84 - 1.73). Sixteen 
patients (62%) randomised to P+C and 19 patients (58%) 
randomised to P+S experienced adverse events (RR 1.07, 95% 
CI 0.7 - 1.63). The types of adverse events were similar in both 
groups, with rash being the most common adverse event. 
Katlama et al.6 assessed 299 patients. Twenty-nine (19%) of 
the 152 patients randomised to P+C died compared with 22 
(15%) of the 147 patients randomised to P+S (RR 1.27, 95% CI 
0.77 - 2.11). We were unable to obtain data on the outcomes 
of patients who crossed over and therefore excluded these 
data from the analysis. One hundred and ten patients (72%) 
randomised to P+C and 117 patients (80%) randomised to P+S 
had complete or partial radiological responses at 6 weeks (RR 
0.91, 95% CI 0.8 - 1.03). Ninety-two patients (60%) randomised 
to P+C and 96 patients (65%) randomised to P+S experienced 
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at least one adverse event (RR 0.93, 95% CI 0.78 - 1.1). Adverse 
events were similar in both groups although skin rash, liver 
toxicity and crystalluria were more common with P+S, while 
diarrhoea was more common with P+C. 
Dannemann et al.5 and Katlama et al.6 were not 
heterogeneous for the outcomes of mortality, adverse events 
and radiological outcome. They were, therefore, analysed 
together for these outcomes. The two treatment arms did 
not differ for death (RR 1.41, 95% CI 0.88 - 2.28), complete or 
partial radiological response (RR 0.95, 95% CI 0.84 - 1.07), or 
adverse events (RR 0.95, 95% CI 0.81-1.11). 
Torre et al.7 assessed 77 patients. There were no deaths 
during the study period. Twenty-eight of 40 patients (70%) 
randomised to TMP-SMX had a good clinical response 
compared with 26 (70%) of 37 patients randomised to P+S 
(RR 1.0, 95% CI 0.74 - 1.33). Twenty-seven patients (68%) 
randomised to TMP-SMX and 23 (62%) randomised to P+S had 
a good radiological outcome (RR 1.09, 95% CI 0.78 - 1.51). Five 
patients (12%) randomised to TMP-SMX and 8 patients (22%) 
randomised to P+S experienced an adverse event (RR 0.58, 95% 
CI 0.21 - 1.61). Skin rash was significantly more common with 
P+S. 
We also compared patients who received TMP-SMX or P+C 
with patients who received P+S. There was no statistically 
significant difference for death (RR 1.51, 95% CI 0.86 - 2.67). 
Discussion
Because of the small number of studies in the final analysis 
it was not possible to conduct subanalysis of studies. Two 
studies (Dannemann et al.5 and Katlama et al.6) compared P+C 
with P+S. These were analysed together for death, radiological 
response, and adverse events. The pooled analysis for 
mortality, radiological outcomes and adverse events revealed 
no differences between the two treatments. Only Danneman et 
al.5 was analysed for clinical response, but no difference was 
found between the two treatments. Therefore P+S and P+C can 
be considered equivalent for the treatment of acute TE in HIV-
infected individuals. 
One of the aims of the review was to identify treatments 
that would be suitable for resource-poor settings where 
sulfadiazine is often not available despite being on the World 
Health Organization essential drugs list (complementary list).8 
TMP-SMX was compared with P+S by Torre et al.7 and was 
not found to be inferior. From this one study the evidence 
suggests that TMP-SMX, which is cheap and readily available 
in developing countries, may be suitable first-line therapy 
for acute TE in HIV-infected individuals. In South Africa 
TMP-SMX is already recommended in the standard treatment 
guidelines9 and essential drugs list as first-line treatment for 
TE.
The available evidence fails to identify any one superior 
regimen for the treatment of TE. No significant difference was 
found between the different treatment regimens. The choice 
of therapy will often be directed by available therapy. Given 
the current evidence, TMP-SMX appears to be an effective 
alternative therapy to P+S for TE in resource-poor settings. 
With the advent of combination antiretroviral therapy in 
high-income countries opportunistic infections such as TE 
have declined. They remain a large problem in resource-poor 
settings where frequently patients present to the health services 
with opportunistic infections and are diagnosed with HIV 
infection at the same time. Large amounts of donor funding 
are currently being devoted to improving care of HIV-infected 
patients in resource-poor settings but the evidence base 
for how to do this is thin. Further evaluations of treatment 
available in resource-limited settings will be important to 
ensure that funds are used efficiently. As a middle-income 
country with a well-developed health service, South Africa is 
ideally placed to conduct trials to determine the ideal treatment 
regimen for TE. Collaboration between centres managing large 
numbers of patients with TE should be encouraged to achieve 
this goal.
We wish to acknowledge Krishma Busgeeth from the South African 
Cochrane Centre, Cape Town, for carrying out the majority of the 
searches for this review. 
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